A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
出版年份 2016 全文链接
标题
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
作者
关键词
-
出版物
CANCER
Volume 122, Issue 15, Pages 2389-2398
出版商
Wiley
发表日期
2016-05-22
DOI
10.1002/cncr.30056
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study
- (2015) Jaime R. Merchan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Metabolic alterations in renal cell carcinoma
- (2015) Francesco Massari et al. CANCER TREATMENT REVIEWS
- Tankyrase Inhibition Blocks Wnt/ -Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
- (2015) O. Arques et al. CLINICAL CANCER RESEARCH
- Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors
- (2015) Timothy J. Hobday et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting PI3 kinase in cancer
- (2015) Todd M. Bauer et al. PHARMACOLOGY & THERAPEUTICS
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
- (2014) C. Fritsch et al. MOLECULAR CANCER THERAPEUTICS
- Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
- (2014) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
- (2013) Maria Serova et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor-like Kinase-1 Ligand Trap, in Patients with Advanced Cancer
- (2013) J. C. Bendell et al. CLINICAL CANCER RESEARCH
- A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma
- (2013) Lauren C. Harshman et al. Clinical Genitourinary Cancer
- ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2013) Bruce E. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma
- (2013) Uday B. Dandamudi et al. JOURNAL OF IMMUNOTHERAPY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
- (2013) Limor Amit et al. PLoS One
- Combination Therapy in Metastatic Renal Cell Cancer
- (2013) Alain Ravaud et al. SEMINARS IN ONCOLOGY
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- (2012) F. Janku et al. CANCER RESEARCH
- Sweet Response: Hyperglycemia and Hypertriglyceridemia as Biomarkers of Clinical Benefit for Everolimus in Patients with Recurrent Endometrial Cancer
- (2012) R. Stone et al. GYNECOLOGIC ONCOLOGY
- Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
- (2012) Naifa L. Busaidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Basic and Therapeutic Aspects of Angiogenesis
- (2011) Michael Potente et al. CELL
- Making sense of cancer genomic data
- (2011) Lynda Chin et al. GENES & DEVELOPMENT
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
- (2011) Nikhil Wagle et al. Cancer Discovery
- The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
- (2010) D. C. Cho et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
- (2010) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
- (2010) Steven JM Jones et al. GENOME BIOLOGY
- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
- (2009) L. M. Ellis et al. CLINICAL CANCER RESEARCH
- Reactive Oxygen Species-generating Mitochondrial DNA Mutation Up-regulates Hypoxia-inducible Factor-1α Gene Transcription via Phosphatidylinositol 3-Kinase-Akt/Protein Kinase C/Histone Deacetylase Pathway
- (2009) Nobuko Koshikawa et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
- (2009) Laura E. MacConaill et al. PLoS One
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started